

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1548)**

**SUPPLEMENTAL ANNOUNCEMENT TO  
THE GRANT OF RESTRICTED SHARES**

Reference is made to the announcement of the Company in relation to the grant of restricted shares dated 1 June 2023 (the “**Previous Announcement**”). Unless otherwise defined, terms used herein shall bear the same meanings as defined in the Previous Announcement.

**THE GRANT OF RESTRICTED SHARES TO THE RSA GRANTEES A PURSUANT TO THE RSA SCHEME 2019**

As disclosed in the Previous Announcement, on 1 June 2023, 6,315,784 RSA Shares A were granted to the RSA Grantees A, being two rotating chief executive officers of the Company.

The Board would like to clarify that all of the 6,315,784 RSA Shares A will be satisfied by the existing Shares of the Company that have been or will be acquired by the Trustee through on-market transactions and are currently held and/or will be held on trust for the RSA Grantees A until the end of each vesting period of the RSA Shares A and be transferred to the respective RSA Grantees A upon satisfaction of the relevant vesting conditions as specified by the Board at the time of making the RSA Grant A. Accordingly, no new Shares will be allotted and issued by the Company as a result of the RSA Grant A, and the RSA Grant A will not result in any dilution on the shareholdings of existing Shareholders of the Company.

**THE GRANT OF RESTRICTED SHARES TO A SERVICE PROVIDER PURSUANT TO THE RSA SCHEME 2021**

As disclosed in the Previous Announcement, on 1 June 2023, 223,234 RSA Shares B were granted to the Consultant pursuant to the RSA Scheme 2021.

The Board would like to supplement that having considered that (i) the Consultant is a service provider who provides strategic business consultancy services to the Group on a continuing or recurring monthly basis in the ordinary and usual course of business which is in the interests of the long term growth of the Group, (ii) the Consultant has extensive experience in the pharmaceutical industry and the services provided are beneficial to the overall business development of the Group, and (iii) the RSA Shares B granted to the Consultant will be vested in three batches on an annual basis between 1 June 2024 and 31 May 2026 which will be an incentive to the Consultant to continue to provide his valuable services to the Group, the Board

believes that the grant to the Consultant can align the interests of the Consultant with the interests of the Company and its Shareholders, motivate the Consultant to commit to the Group's future development and growth, and strengthen his long-term service commitment to the Group, which therefore is in line with the purpose of the RSA Scheme 2021.

## **LISTING RULES IMPLICATIONS**

In relation to the RSA Grant B to the RSA Grantees B, being the Employees and the Consultant of the Company, the new Shares to be allotted and issued by the Company to the Trustee or the nominee account represent approximately 0.2424% of the Company's issued share capital as at the date of the Previous Announcement and approximately 0.2418% of the Company's enlarged issued share capital after the issue. Application will be made by the Company to the Listing Committee of the Stock Exchange for the grant of approval for the listing of, and permission to deal in, the 5,135,200 new Shares to be issued.

The Company will issue and allot 5,135,200 RSA Shares B to the Trustee or the nominee account of the Company (of which the beneficial owner will be the relevant RSU Grantees B) pursuant to the general mandate (the "**General Mandate**") granted by the Shareholders of the Company at the annual general meeting of the Company held on 25 May 2023 and in accordance with the terms of the RSA Scheme 2021. Pursuant to the General Mandate, the Directors may exercise the powers of the Company to allot and issue up to 423,611,705 Shares, representing 20% of the total number of Shares in issue as at the date of the annual general meeting. As at the date of this announcement, no Shares have been issued under the General Mandate. As such, after the RSA Grant B, 418,476,505 Shares will remain available for future allotment and issue of Shares under the General Mandate.

Save as aforesaid, all other information as set out in the Previous Announcement remain unchanged and shall continue to be valid for all purposes, while this announcement is supplemental to and should be read in conjunction with the Previous Announcement.

By order of the Board  
**GenScript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 15 June 2023

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only